The effects of anti-mullerian hormone, antral follicle count, and follicle stimulating hormone values on pregnancy outcomes in a case with polycystic ovary syndrome

Authors

  • CELAL AKDEMİR
  • Fatma Ferda Verit

DOI:

https://doi.org/10.46328/aejog.v4i3.127

Keywords:

Infertility, Pregnancy, Anti-mullerian hormone, Polycystic ovary syndrome, AFC

Abstract

Objective: In this study, it was aimed to predict pregnancy by anti-mullerian hormone, follicle-stimulating hormone, and antral follicle count values of infertile patients with PCOS.

Methods: This retrospective study has been conducted on 555 patients diagnosed with PCOS (polycystic ovary syndrome) according to the Rotterdam Criteria, referred for infertility in the IVF Clinic of Istanbul Training and Research Hospital in the 2010-2019 study. Clinical pregnancy results have been analyzed together with anti-mullerian hormone, antral follicle count, and follicle-stimulating hormone levels.

Results: The age of the patients within the group of clinical pregnancy is significantly higher than the group without pregnancy (p ˂ 0.05). Follicle-stimulating hormone (iu/ml) and anti-mullerian hormone (ng/ml) values do not differ significantly (p 0.05) in the group with and without clinical pregnancy. For the group with clinical pregnancy, the antral follicle count value is found to be significantly higher (p ˂ 0.05) than the group without pregnancy.

The age of the patients in the group with clinical pregnancy was found to be significantly higher than the group without pregnancy. (p ˂ 0.05). Follicle stimulating hormone (iu/ml) and anti-müllerian hormone (ng/ml) values did not differ significantly in the group with and without clinical pregnancy (p 0.05). Antral follicle count value was found to be significantly higher in the group with clinical pregnancy than in the group with out pregnancy (p ˂ 0.05).

Although AFC was found to be significantly higher in the group with clinical pregnancy than in the non-pregnant group, it was examined diagnostically by ROC analysis, but the diagnostic capacity of this variable to distinguish between pregnant and non-pregnant women was not found to be sufficient. (AUC<0.70).

Conclusion: We found that anti-mullerian hormone and follicle-stimulating hormone are not related to clinical pregnancy outcomes in the infertile patient group diagnosed with PCOS (polycystic ovary syndrome). Plus, although the AFC value in the group with pregnancy was significantly higher than the group without pregnancy, its diagnostic capacity was not found to be sufficient.

Downloads

Published

2023-02-07

How to Cite

1.
AKDEMİR C, Verit FF. The effects of anti-mullerian hormone, antral follicle count, and follicle stimulating hormone values on pregnancy outcomes in a case with polycystic ovary syndrome. Aegean J Obstet Gynecol [Internet]. 2023 Feb. 7 [cited 2024 Jul. 24];4(3):57-60. Available from: https://aejog.com/index.php/aejog/article/view/127